MedTrace Logo

Benefits of GIK in Cardiac Surgery Patients

NCT01516138 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 930

Last updated 2014-10-31

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effects of modified glucose - insulin - potassium (GIK) therapy in cardiac surgery patients undergoing cardiopulmonary bypass (CPB).

Conditions

  • Cardiac Surgery
  • Cardiopulmonary Bypass

Interventions

DRUG

GIK

Intravenous solution was started at about 10 minutes before general anesthesia, running at a rate of 1 mL/kg/h for 12.5 hours.

DRUG

Control

Intravenous solution was started at about 10 minutes before general anesthesia, running at a rate of 1 mL/kg/h for 12.5 hours.

Sponsors & Collaborators

  • Xijing Hospital

    lead OTHER

Principal Investigators

  • Dinghua Yi, MD,PhD · Deparment of cardiovascular surgery, XiJing hospital, Fourth Military Medical University

  • Qin Cui, MD,PhD · Deparment of cardiovascular surgery,XiJing hospital,Fourth Military Medical University

  • Jia Li, MD,PhD · Deparment of Physiology, Fourth Military Medical University

  • Feng Gao, MD,PhD · Deparment of Physiology, Fourth Military Medical University

  • Kun Zhao, MD · Deparment of cardiovascular surgery, XiJing hospital,Fourth Military Medical University

  • Shiqiang Yu, MD,PhD · Deparment of cardiovascular surgery, XiJing hospital, Fourth Military Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-02-29
Primary Completion
2013-03-31
Completion
2022-02-28

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01516138 on ClinicalTrials.gov